+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Establishment and characterization of a chordoma cell line from the tissue of a patient with dedifferentiated-type chordoma

Establishment and characterization of a chordoma cell line from the tissue of a patient with dedifferentiated-type chordoma

Journal of Neurosurgery. Spine 25(5): 626-635

OBJECTIVE Chordoma is a rare bone tumor of the axial skeleton believed to originate from the remnants of the embryonic notochord. The available tumor cells are characteristically physaliferous and express brachyury, a transcription factor critical for mesoderm specification. Although chordomas are histologically not malignant, treatments remain challenging because they are resistant to radiation therapy and because wide resection is impossible in most cases. Therefore, a better understanding of the biology of chordomas using established cell lines may lead to the advancement of effective treatment strategies. The authors undertook a study to obtain this insight. METHODS Chordoma cells were isolated from the tissue of a patient with dedifferentiated-type chordoma (DTC) that had recurred. Cells were cultured with DMEM/F12 containing 10% fetal bovine serum and antibiotics (penicillin and streptomycin). Cell proliferation rate was measured by MTS assay. Cell-cycle distribution and cell surface expression of proteins were analyzed by fluorescence-activated cell sorting (FACS) analysis. Expression of proteins was analyzed by Western blot and immunocytochemistry. Radiation resistance was measured by clonogenic survival assay. Tumor formation was examined by injection of chordoma cells at hindlimb of nude mice. RESULTS The putative (DTC) cells were polygonal and did not have the conventional physaliferous characteristic seen in the U-CH1 cell line. The DTC cells exhibited similar growth rate and cell-cycle distribution, but they exhibited higher clonogenic activity in soft agar than U-CH1 cells. The DTC cells expressed high levels of platelet-derived growth factor receptor-β and a low level of brachyury and cytokeratins; they showed higher expression of stemness-related and epithelial to mesenchymal transition-related proteins than the U-CH1 cells. Intriguingly, FACS analysis revealed that DTC cells exhibited marginal surface expression of CD24 and CD44 and high surface expression of CXCR4 in comparison to U-CH1 cells. In addition, blockade of CXCR4 with its antagonist AMD3100 effectively suppressed the growth of both cell lines. The DTC cells were more resistant to paclitaxel, cisplatin, etoposide, and ionizing radiation than the U-CH1 cells. Injection of DTC cells into the hindlimb region of nude mice resulted in the efficient formation of tumors, and the histology of xenograft tumors was very similar to that of the original patient tumor. CONCLUSIONS The use of the established DTC cells along with preestablished cell lines of chordoma may help bring about greater understanding of the mechanisms underlying the chordoma that will lead to therapeutic strategies targeting chordomas.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 057796455

Download citation: RISBibTeXText

PMID: 27314550

DOI: 10.3171/2016.3.spine151077

Related references

Molecular characterization of chordoma xenografts generated from a novel primary chordoma cell source and two chordoma cell lines. Journal of Neurosurgery. Spine 21(3): 386-393, 2014

Establishment and characterization of a novel chordoma cell line: CH22. Journal of Orthopaedic Research 30(10): 1666-1673, 2012

UM-Chor1: establishment and characterization of the first validated clival chordoma cell line. Journal of Neurosurgery 128(3): 701-709, 2018

Case report 576. Anaplastic sacrococcygeal chordoma (dedifferentiated chordoma). Skeletal Radiology 18(7): 561-564, 1989

Dedifferentiated chordoma arising in irradiated sacral chordoma. Radiation Medicine 15(2): 109-111, 1997

Expression of MDR1, HIF-1α and MRP1 in sacral chordoma and chordoma cell line CM-319. Journal of Experimental and Clinical Cancer Research 29: 158, 2010

Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. Journal of Neurosurgery 120(2): 331-336, 2014

Establishment and characteristics of a human chordoma cell line. Zhonghua Zhong Liu Za Zhi 25(3): 234-237, 2003

Three cases of intracranial chordoma. Typical chordoma and chondroid chordoma. No Shinkei Geka. Neurological Surgery 12(5): 591-598, 1984

Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1. International Journal of Oncology 40(2): 443-451, 2012

Axial chordoma and parachordoma (soft tissue chordoma): two of a kind: report of two cases with primary diagnosis on fine-needle cytology samples. Diagnostic Cytopathology 39(7): 475-481, 2011

Sarcomatoid chordoma: chordoma with a massive malignant spindle-cell component. Skeletal Radiology 29(12): 721-725, 2000

Incipient chordoma: a report of two cases of early-stage chordoma arising from benign notochordal cell tumors. Modern Pathology 18(7): 1005-1010, 2005

Cytogenetics and molecular genetic characterization of the first human chordoma cell line U-CH1. Pathology Research & Practice 196(6): 352, 2000

Derivation and characterization of an extra-axial chordoma cell line (EACH-1) from a scapular tumor. Journal of Bone and Joint Surgery. American Volume 92(5): 1231-1240, 2010